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BDNFThe search for biomarkers in cognition has been the focus of a large part of the research on patients suffering
from schizophrenia. The scientiﬁc literature is heterogeneous, and few studies establishing an integrative
model of pathogenesis and therapeutic response are available in this ﬁeld. In this review, we aimed to
summarize three essential aspects correlated with cognitive performance: 1) the relationship between
inﬂammation and cognition in schizophrenia, 2) the role of prolactin in cognition, and 3) the association
between cognition and neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF).
Several studies support the association of inﬂammatory markers with cognitive status in schizophrenia. In
recent decades, the development of effective therapies for cognitive impairment in schizophrenia has focused
on the search for anti-inﬂammatory and immunomodulatory medications. Conversely, the implications of
prolactin and its functions in cognition, the transition to psychosis and the diagnosis and prognosis of
schizophrenia have been established independent of antipsychotic treatment. With regard to neurotrophic
factors, a recent study has correlated BDNF levels with cognitive recovery in schizophrenic patients treated
with cognitive remediation.
We conclude that although there is a diversity of biomarkers focused on cognitive function in schizophrenia,
BDNF is the biomarker that has accumulated the vast majority of evidence in the current literature.og.2015.06.002.© 2015 Published by Elsevier Inc.1. The search for biomarkers for cognition
The Food and Drug Administration (FDA) deﬁnes a biomarker as “a
characteristic that is objectivelymeasured and evaluated as an indicator
of normal biological processes, pathogenic processes, or pharmacolog-
ical responses to therapeutic intervention” (Atkinson et al., 2001). The
current scientiﬁc literature suggests that thedeﬁnition of biomarkers for
psychiatric disorders increases the potential responses to a range of
psychopharmaceuticals and improves studies focused on the develop-
ment of effective therapies for these disorders through better validation
of objectivemeasures and stratiﬁcation of patients as a function of these
markers (Tandon et al., 2010).
During the last few decades, limited scientiﬁc evidence in the ﬁeld
of biomarkers has stimulated scientiﬁc contributions through inves-
tigations into the principal etiopathogenetic hypotheses of psychiatric
disorders. Speciﬁcally, focusing on studies of schizophrenia and
related disorders, the last few years have seen increasing interest in
deﬁning new biomarkers that are valid, reliable, and useful in clinical
practice and that allow researchers to confront this century’s primary
challenges to psychiatric biology.The proposed models were developed to deﬁne restrictive pheno-
types that can integrate a diversity of proposed hypotheses on
schizophrenia (García-Bueno et al., 2014b). A systemic and meta-ana-
lytical review reveals the existence of proinﬂammatory dysregulation in
schizophrenia and suggests that numerous cytokines involved in these
processes should be the focus of new research aimed at deﬁning
biological markers that can be used to measure disease progression
(Upthegrove et al., 2014). In this context, molecular genetics, plasma and
cerebrospinal ﬂuid analysis, and structural and functional neuroimaging
are attractive and promising ﬁelds in studies focused on biomarkers
(Oertel-Knöchel et al., 2011; Penadés et al., 2013).
One review emphasizes that in the last few decades, candidate
genes and proteins have been described that show characteristics that
are in line with the nature of biomarkers (Chana et al., 2013). Those
authors indicate that the relationship between the majority of
biological markers and the symptomology that arises in psychiatric
disorders should be the subject of careful, in-depth study. Addition-
ally, biological psychiatry has been confronted by numerous difﬁcul-
ties in the study of said biomarkers, one of which is the relative
inconsistency of some clinical diagnoses. The aforementioned fact has
allowed some researchers to relate numerous markers with the
cardinal symptoms of psychiatric disorders. A recent systemic review
suggests that some discoveries indicate the presence of biological
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(Ribeiro-Santos et al., 2014).
This study serves as a review of the scientiﬁc literature focused on
biomarkers of cognitive state in patients suffering from schizophrenia.
The objectives of this study are as follows: (1) to highlight the need to
discuss the ﬁeld’s primary ﬁndings, given that cognitive performance
has a direct impact on schizophrenic patients’ functionality, and (2) to
provide evidence of markers in clinical responses to therapies
established by the scientiﬁc community that may have promising
and hopeful results. This review is focused on three high-interest
topics in the ﬁeld of biomarkers. First, we review the relationship
between cognition and inﬂammation in schizophrenia; second, we
describe the potential role of prolactin in cognition; and third, we
review the link between cognition and neurotrophic factors, in
particular BDNF.
2. Cognition and inﬂammation in schizophrenia
We are in the midst of experiencing a reformulation of the classic
concept of schizophrenia, now seen as a mixture of symptoms that, from
the beginning, has a multisystem impact (Insel, 2010; Kirkpatrick, 2009).
In this context, numerous hypotheses involving the immune system and
inﬂammatory processes of both the peripheral and central nervous
systems have been proposed as etiological explanations for schizophrenia
and relateddisorders. These processes seem to be inﬂuencedby a series of
genetically predisposed and environmental factors that could make
critical contributions to the progressive nature of these pathologies
(Meyer, 2011).
An inﬂammatory response is an adaptivemechanism that enables the
body to cope with numerous challenges. Under prolonged pathological
conditions, however, the continuedmaintenanceof this response couldbe
detrimental. The precise regulation of the entire inﬂammatory response
process involves complex endogenous counterbalancing mechanisms
that control the effects of ﬁxed, and potentially damaging, proinﬂamma-
tory intermediaries (Meyer, 2011).
In the last ﬁfteen years, renewed interest has focused on these
immune and inﬂammatory changes and the consequences of related
oxidative and nitrosative metabolic issues, including key physiopath-
ological mechanisms involved from the onset of schizophrenia and
other related psychiatric disorders. Consequently, a considerable body
of study has identiﬁed a spectrum of inﬂammatory and immunolog-
ical dysfunction in schizophrenia. The primary evidence that supports
the existence of this spectrum is as follows:
a) Genetic studies, including the Genome-Wide Association Study
(GWAS) with large population samples, that have described
genetic variations of the major histocompatibility complex and
of genes expressed in tissue with important roles in immune or
inﬂammatory responses (Schizophrenia Working Group of the
Psychiatric Genomics, 2014; Shi et al., 2009; Stefansson et al.,
2009). There is also evidence of the upregulation of genes
linked to inﬂammation in brain tissue (Drexhage et al., 2010;
Saetre et al., 2007).
b) Ecological studies that demonstrate an increased presentation
of autoimmune illnesses and serious infections in this popu-
lation (Benros et al., 2011; Torrey et al., 2012).
c) At the peripheral level, multiple studies have described an
elevation of plasma proinﬂammatory cytokines, which are key
mediators in the regulation between the central nervous
system and the immune system (review in Miller et al.
(2011)). Given that the majority of infectious agents do not
cross the placenta, prenatal studies have identiﬁed proinﬂam-
matory cytokines as potential mediators of the harmful effects
of fetal brain infections (Fineberg and Ellman, 2013). Addi-tionally, studies have recognized an increase in other periph-
eral proinﬂammatory mediators, such as prostaglandin E2 and
COX activity (Das and Khan, 1998; Kaiya et al., 1989).
d) Although substantial interest has focused on proinﬂammatory
processes activated in schizophrenia, the role of anti-inﬂam-
matory signaling has attracted somewhat less attention in this
context (Meyer, 2011). The stimulation of anti-inﬂammatory
cytokines, such as IL-4, IL-10, and IL-17, appears to be a
mechanism provoked by various antipsychotics to regulate
uncontrolled and potentially harmful inﬂammation in schizo-
phrenia, suggesting an alternative method of action for
dopaminergic blocking (Maes et al., 1995; Meyer, 2011; Sugino
et al., 2009).
e) Disequilibrium has been recognized to exist in speciﬁc pro/
anti-inﬂammatory mediators in peripheral blood (Martinez-Gras
et al., 2011). This disequilibrium,which involves the inﬂammatory
pathway of nuclear transcription factor κB (NFκB) and
the anti-inﬂammatory pathway of prostaglandin 15-deoxy-
PGJ2 (15d-PGJ2), is evident from the ﬁrst psychotic episode
(FPE) (Garcia-Bueno et al., 2014a) and increases as the illness
progresses (García-Bueno et al., 2014b), supporting the existence
of dysregulation of inﬂammatory equilibrium in patients at an
early stage of psychotic disorder. Because of its soluble nature, one
notable ﬁnding of these studies is that the anti-inﬂammatory
mediator 15d-PGJ2 can be used as a plasma biomarker for FPEs
(Garcia-Bueno et al., 2014a; García-Bueno et al., 2014b).
f) At the level of the central nervous system (CNS), the activation
of cerebral microglia, the CNS’s ﬁrst line of defense, has been
described (Benarroch, 2013) in post-mortem studies using
positron emission tomography (van Berckel et al., 2008).
g) Disequilibrium of the immune response to a signiﬁcant
humoral response (increased levels of IL-1, -4, -6, -10, and
-12 in patient plasma and a large cell ratio (LCR)), a ﬁnding that
was correlated with a poor prognosis (Potvin et al., 2008).
h) These data have supported clinical trials of non-steroidal anti-in-
ﬂammatory drugs (NSAIDs) as contributing treatments in psy-
chotic disorders. Recent meta-analyses show conditional evidence
of the favorable symptomatic effects of NSAIDs, especially aspirin,
N-acetylcysteine, and estrogens, as drugs that complement
antipsychotics (Nitta et al., 2013; Sommer et al., 2014).
i) Various studies have linked alterations of the endocannabinoid
system (ECS) with schizophrenia (for a review, see Zamberletti
et al. (2012)). The ECS has been suggested as a principal
homeostatic system involved in the regulation of complex
neuroimmune interactions in a range of neuropathological
scenarios (Wolf et al., 2008). Studies on schizophrenia have
focused primarily on the CB1 and CB2 receptors (Eggan et al.,
2008; Ishiguro et al., 2010) and on principal endogenous
ligands (Giuffrida et al., 2004; Leweke et al., 1999; Muguruza
et al., 2013). There is also recent evidence of peripheral
dysregulation of this system during FPEs (Bioque et al.,
2013). Converging lines of evidence indicate that endocanna-
binoids modulate cognitive processes in both animals and
humans (Morena and Campolongo, 2013).
Recent studies have linked immune and inﬂammatory changes to
cognitive performance in numerous illnesses, including schizophrenia.
Speciﬁcally, cytokines such as interleukins 1 and 6 (IL-1, IL-6) and tumor
necrosis factor (TNF) have been linked to cognitive deterioration and
othernegative symptoms(Meyeret al., 2011). Evidence suggests that IL-1,
IL-6, and TNF could have a central role in maintaining biological
characteristics at a molecular level; characteristics such as synaptic
plasticity, neurogenesis, or neuromodulation; and cellular mechanisms
involved in learning,memory, andcognition (McAfooseandBaune, 2009).
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(Muller et al., 2005), inhibiting the strength of synaptic connectivity and
affecting memory consolidation. Overall, these results link inﬂammatory
markers to cognitive performance in schizophrenia, suggesting that the
presence of inﬂammation is associated with poor cognitive performance
(see Ribeiro-Santos et al., 2014). Various physiopathological mechanisms
havebeendeveloped to attempt toexplain the inﬂammatorymechanisms
that underlie cognitive deterioration in schizophrenia and related
disorders, includingmicroglial activation,monoaminergic disequilibrium,
cerebral abnormalities, and the kynurenine pathway (Ribeiro-Santos
et al., 2014). Non-speciﬁc inﬂammatory markers, such as the elevation of
C-reactive protein, have been linked to cognitive function but not to other
psychopathological symptoms(Dickersonet al., 2007), thus indicating the
potential use of particular inﬂammatory mediators as biomarkers for
cognitive state.
Antipsychotic drugs (via the dopaminergic antagonism of D2-re-
ceptors) form the basis of the current treatment of schizophrenia and
related disorders. Although these drugs have been shown to be
effective in treating positive symptoms (such as hallucination and
delirium) in the majority of patients, they have also shown to have
poor results in treating both negative symptoms and cognitive
deﬁciencies (Correll, 2014; Meyer et al., 2011). Because these
neurocognitive dysfunctions have such a higher impact on the
functional result than the positive symptoms of schizophrenia do
(Green et al., 2000), the focus of pharmacotherapeutic treatment has
shifted toward future drugs’ potential efﬁcacy in improving cognition
(Correll, 2014). A few studies have produced data on the effect of
anti-inﬂammatory or immunomodulatory drugs as complementary
treatment to antipsychotics for patients with schizophrenia. The use
of celecoxib (a cycloxygenase-2 inhibitor), along with risperidone
treatment, has shown a beneﬁcial effect on the Positive and Negative
Syndrome Scale (PANSS) cognitive factors (Muller et al., 2002).
Minocycline, an antibiotic that also produces immunomodulatory
activity, can also improve cognitive functioning during the early
phases of schizophrenia (Levkovitz et al., 2010). These data suggest
that FPEs can be treated in the subgroup of patients who achieve the
most beneﬁt from anti-inﬂammatory treatments. The repeated
association between inﬂammation and cognition supports clinical
tests using immunomodulatory or anti-inﬂammatory drugs as
procognitive drugs for schizophrenia and related disorders (Kroken
et al., 2014), opening up a promising new ﬁeld for the treatment of
these patients and allowing clinics to monitor their progress.
3. Cognition and prolactin
Prolactin is a peptide hormone that historically has been studied
for its function in lactation; it is responsible for stimulating milk
production during the postpartum period, thus giving the hormone its
name. Although it was initially thought to be secreted only by
lactotrophic cells of the anterior pituitary gland, various mammal
studies have expanded the physiology of prolactin. Other cells outside
the anterior pituitary have been found to produce the hormone, such
as cells in the skin, the mammary glands, the myometrium, the
prostate gland, the placenta, and the immune system (Bernichtein
et al., 2010; Horseman and Gregerson, 2013). Its function has similarly
been expanded by examining the locations of its receptors, which are
found in the mammary glands, ovaries, pituitary gland, heart, lungs,
thymus, pancreas, kidneys, liver, adrenal glands, uterus, skeletal
muscle, vascular system, and various parts of the central nervous
system (Grattan and Kokay, 2008).
In addition to its role in lactation, prolactin has been implicated in
maternal behavior (Ben-Jonathan et al., 2008), sexual behavior (in
equilibrium with dopamine), energetic balance, feeding behavior,
stress, pain, anxiety, and neurogenesis (Bernichtein et al., 2010).Although its secretion has been linked to clinical and biological factors
such as age, sex, body mass index, steroid hormones (such as
luteinizing, follicle-stimulating, and thyroid-stimulating hormones),
temperature, nutrition (leptin and ghrelin), and stress, its primary
limiting factor is the inhibitory activity of hypothalamic dopamine.
Certain endocrine neurons from the hypothalamus – i.e., the
tuberoinfundibular neurons of the arcuate nucleus – secrete dopa-
mine; through the D2 dopaminergic receptors of lactotrophic cells,
these neurons inhibit the secretion of prolactin.
Prolactin levels act as a daily, oscillatory, and even seasonal circadian
rhythm,with bothpulsating andbasalmodes of secretion. Thebasal levels
differ based on sex, with women secreting more than men (Roelfsema
et al., 2012). Studies of the CNS have resulted in an increased interest in
the function of prolactin and its receptors in the brain. The expression of
brain prolactin receptors has been studied primarily in lower mammals
(rodents), emphasizing the greater presence of receptors in speciﬁc zones
– suchas the choroidplexus, thehippocampus, thehypothalamus, and the
preoptic area – during pregnancy and lactation; presumably, this is
attributable to direct action by prolactin, placental lactogen, and sex
steroids (Grattan, 2002).
The interaction between prolactin receptors and various sex-steroidal
(estradiol, testosterone), leptin, ghrelin, and adiponectin receptors results
in variations in the functionality of the CNS. In addition to speciﬁc
functions in the regulation of energetic balance (Le et al., 2011) and
physiological responses to stress (Jaroenporn et al., 2007), there are also
studies that relate prolactin to cognition. Animal studies in lower
mammals show an association between changes in prolactin levels and
various cognitive processes. In genetically modiﬁed animals, a prolactin
deﬁcit has been associated with lowered neurogenesis in the hippocam-
pus, along with alterations in both learning and memory (Walker et al.,
2012). In another study, elevated levelsofprolactinwereassociatedwitha
change in the capacity for object recognition with no modiﬁcation in
spatial learning (Torner et al., 2013).
Studies in humans (primarily pregnant women) have also been
carried out to investigate the role of prolactin on cognitive processes.
These studies have indicated that variations in steroid hormones
during pregnancy resulted in changes to both the neural structure and
the activity of brain regions focused on information storage and the
modulation of emotional responses. Initially, studies comparing
cognitive function in pregnant and postpartum women with that in
non-pregnant women found these changes in verbal memory and
processing speed. The differences indicated poorer performance
during pregnancy and the postpartum period, highlighting an inverse
relationship between verbal memory and executive function on the
one hand and prolactin levels on the other (Henry and Sherwin,
2011). However, the results were inconclusive because although an
association with spatial recognition memory was detected, a later
comparative study of cognitive function during each trimester of
pregnancy and three months postpartum was unable to identify the
hormones linked to these differences (Farrar et al., 2014).
As mentioned above, various clinical factors can modify prolactin
levels, including age, sex, body-mass index (Roelfsema et al., 2012),
and gonadal estrogen levels. According to this line of argument, the
lowering of prolactin levels in menopausal women is linked to
decreased estrogen secretion, just as in older men in which a slight
increase in the levels of prolactin is associated with higher amounts of
estradiol (Vermeulen et al., 2002). Aging is also associated with
changes in circadian rhythm, reﬂecting variations in nocturnal
dopaminergic activity and, consequently, in the secretion of prolactin.
Similarly, a Portuguese study has correlated the combination of
prolactin and sex estrogens in adulthood with cognitive patterns
during old age (Castanho et al., 2010). In this study, both prolactin and
dehydroepiandrosterone were the two hormones that were the most
correlated with cognitive patterns. In men, elevated levels of prolactin
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wellbeing and poorer moods. A study assessing cognition and
mathematical abilities in university students found a signiﬁcant
difference between the sexes at the cognitive and hormonal levels;
women with low levels of prolactin had higher mathematical ability,
whereas those with high levels of prolactin had higher spatial ability
(Amani et al., 2012).
Because of prolactin’s functional and physiological abilities, its
study in the ﬁeld of neuroscience has historically been limited to the
hyperprolactinemia associated with the dopaminergic block caused
by antipsychotic drugs. The consequences of this pathologic increase
in prolactin depend on the patient’s sex and can produce a wide
variety of clinically relevant adverse effects, including galactorrhea,
amenorrhea, infertility, sexual dysfunction, osteopenia, and cardio-
vascular pathologies in both sexes (Byerly et al., 2007).
Nevertheless, during the last few years, with increased research into
cognition as a nuclear dimension of serious mental disorders (schizo-
phrenia and related psychotic disorders, bipolar disorder), various studies
have evaluated the function of prolactin in the cognition spectrum. One
study of patientswith early psychosis (less than three years since the ﬁrst
signs of symptoms) showed that elevated levels of prolactin were
associated with deﬁcits in processing speed independent of the use of
antipsychotic drugs (Montalvo et al., 2014). There is considerable
controversy surrounding these results, however, because another study
of cognition in male patients with schizophrenia demonstrated that
prolactin did not interfere with the link between sex steroids, such as
testosterone, and cognitive function (Moore et al., 2013). A critical
evaluation of those results, however, highlights the possibility of a
beta-error in using subgroups with small sample sizes. Similarly, an
investigation of patients of both sexes diagnosed with chronic schizo-
phrenia and actively treated with antipsychotics found a link between
prolactin and cognitive function; nevertheless, it could not demonstrate a
direct association using the cognitive parameters measured with the
Mini-Mental test (Ichioka et al., 2012).
Broadly speaking, this ﬁnding will have future implications in the
ﬁeld of cognitive function because earlier studies involving patients
treated with antipsychotics showed a link between the use of a partial
dopaminergic agonist (aripiprazol), which could decrease prolactin
levels, and an effective reduction in hyperprolactinemia, better
clinical psychopathology, and reduced secondary motor effects but
no improvement in cognitive function (Lee et al., 2013). A previous,
similar approach did not evaluate prolactin levels (although, a priori
through pharmacodynamics, reduced prolactin levels were expected)
but did associate the concomitant use of partial dopaminergic agonists
with improved processing speed but worsened (certain) cognitive
functions (Yasui-Furukori et al., 2011). This same group had
previously evaluated decreased prolactin levels in women undergoing
antipsychotic treatment; the decrease was linked to the use of a
partial dopaminergic agonist, but no differences were found in the
women’s cognitive evaluations (Yasui-Furukori et al., 2010).
In summary, prolactin is a peptide hormone whose physiology is
the subject of continuous study and widespread development. It
shows numerous functions at the level of the CNS involved in
hormonal interaction with systems of energetic balance, stress, or
reward. However, recent data suggest new implications in the
relationship between neurogenesis and cognition that, in the future,
could modify our understanding of this hormone as a key element in
the transition to (Aston et al., 2010), prognosis of, and diagnosis of
(Garcia-Rizo et al., 2012) schizophrenia.
4. Cognition and neurotrophic factors: BDNF
Neurotrophins are growth factors that facilitate the development
and survival of nerve cells. They are thus essential for proper neuronfunctioning and improve their survival by preventing the triggering of
cell death. BDNF is likely the best-studied neurotrophin both in basic
research and in relation to various clinical syndromes, including
schizophrenia. Its relevance has been highlighted both in more basic
neurobiological processes, such as neural plasticity, differentiation,
and survival, and in higher cognitive processes, such as learning and
memory (Bekinschtein et al., 2008; Nakajo et al., 2008). There is not
yet a complete consensus on how to measure BDNF, nor even a
standard protocol for collecting plasma BDNF. Nevertheless, the
enzyme-linked immunosorbent assay (ELISA) techniques – based on
the methods described by Metzger et al., 1981 – are the most
prevalent within the BDNF literature; these techniques have been
shown to have a high degree of sensitivity and reliability in
determining serum and plasma levels within blood samples. Addi-
tionally, the procedure has been validated in signiﬁcant demographic
samples (Trajkovska et al., 2007). Samples tend to be extracted from
peripheral activity because of the supposed difﬁculty of obtaining
BDNF from the brain. The data suggest a correlation between BDNF
levels in the brain and in peripheral plasma (Karege et al., 2002).
Unfortunately, studies on the concentrations of BDNF serum levels
in patients with schizophrenia have had contradictory results, leaving
open the question of this relationship and necessitating additional
research and data. Most of the studies that compare levels of BDNF in
samples of schizophrenic patients and healthy controls showed that
patients with schizophrenia have a lower concentration of BDNF
(Grillo et al., 2007; Ikeda et al., 2008; Tan et al., 2005; Xiu et al., 2009;
Zhang et al., 2007). Other studies have not found differences between
the two groups, instead showing that levels are elevated in patients
with schizophrenia (Gama et al., 2007; Reis et al., 2008). These
apparently contradictory results and conclusions have been analyzed
extensively in a meta-analysis study that provided a better interpre-
tation of the results. Green et al. (2011) performed a rigorous
selection of the published reports and concluded that the serum
concentration of BDNF in patients with schizophrenia was found to be
lower than that in healthy patients. This result seems to apply not only
to patients undergoing pharmacological treatment but also to patients
who have never been medicated. The results also seem to apply
evenly regardless of sex. Finally, Green et al. (2011) used meta-re-
gression techniques to demonstrate that BDNF and age were
signiﬁcantly correlated, with lower levels of BDNF corresponding to
older age. However, no relationship was found between BDNF levels
and antipsychotic dosage. We can conclude that in light of the
published studies and themeta-analysis performed on them, and after
controlling for methodological aspects and sample heterogeneity,
blood BDNF levels are lower in patients with schizophrenia than in
healthy individuals.
The consequences of this potential decrease in BDNF levels in
patients with schizophrenia are important in light of this neuro-
trophic factor’s impact on cognition. Tests have linked BDNF with the
formation of dendritic spines and branches, indicating that BDNF acts
as an authentic regulator of axonal growth. For example, it has been
suggested that learning and memory procedures produce a synapse
strengthening effect, resulting in long-term potentiation. Speciﬁcally,
the process of synaptic strengthening appears to be mediated by
receptors linked to BDNF, such as tyrosine-receptor kinase B (TrkB)
(Gärtner et al., 2006; Minichiello et al., 1999). Numerous studies have
even obtained correlations between the levels of BDNF and various
aspects of cognition in patients diagnosed with schizophrenia. Zhang
et al. (2012) found a signiﬁcant correlation between reduced BDNF
levels and the presence of cognitive changes in a large sample of
admitted patients. Niitsu et al. (2011) used a patient sample to
successfully predict cognitive functioning based on the levels of a
precursor to BDNF; their results demonstrated considerable sensitiv-
ity and speciﬁcity.
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schizophrenia and plays a crucial role in cognitive processes, it has
been proposed as a biomarker for this mental disorder and, more
speciﬁcally, as a biomarker for cognitive variability in schizophrenia.
However, it does not appear that sufﬁcient information exists to
support this proposal, which, although promising, is unsatisfactory. At
any rate, as we have indicated previously, a biomarker should have
the characteristics of indicating normal biological processes, patho-
logical processes, and therapeutic responses. With respect to the ﬁrst
characteristic, BDNF seems to play a large role in the processes
responsible for cognition, especially in learning and memory. Its role
as a regulator of axonal and dendritic growth has been demonstrated,
as has its role of regulating neurogenesis in adults. Tests illustrate that
long-term potentiation produced in the hippocampus as a result of
learning is associated with the TrkB BDNF receptor. The second
biomarker characteristic is demonstrated in the ﬁnding that the BDNF
serum levels of patients with schizophrenia are lower than those of
healthy subjects. This result is observed both in chronic patients and
in those suffering their ﬁrst psychotic episode. Speciﬁcally, neuroim-
aging studies link low levels of serum BDNF with reduced hippocam-
pal volumes. The ﬁnal step, therefore, is to determine the role of BDNF
as a marker of therapeutic response. Numerous studies indicate that
typical antipsychotics could diminish BDNF expression, whereas
atypical drugs increase it. These data are still preliminary, however,
and have only been investigated in animal models. Another study
investigated the ability of cognitive treatment to augment serum
levels of BDNF. The study sought to establish a statistically signiﬁcant
correlation between improved cognition and an increase in BDNF
levels in the group that was provided with cognitive therapy.
Although the study has yet to be duplicated, it has opened the door
to promising research (Vinogradov et al., 2009).
BDNF’s role as a biomarker has not been completely established by
the data and results obtained thus far. For example, its speciﬁcity to
schizophrenia has not been demonstrated; decreased levels of BDNF
have also been found in patients with neurodegenerative disorders
and other neuropsychiatric ailments. Nevertheless, BDNF’s character-
ization as a biomarker for the cognitive dimension of schizophrenia
appears to be a promising line of investigation, although more study
and analysis on this relationship need to be performed (Penadés et al.,
2013). Choosing BDNF as an indicator of the cognitive dimension of
schizophrenia, while tempting, remains premature.
5. Conclusions
In the last decade, primarily because of debates around current
clinical diagnostic criteria and psychopathological multidimensional-
ity, there has been growing interest in the study of biological markers
related to schizophrenia, speciﬁcally in certain quantiﬁable aspects of
schizophrenia such as cognitive function. The interest in presenting
objective biomarkers that are distanced from potential inter-observer
subjectivity has spurred the development of speciﬁc ﬁelds within
mental pathology that are more easily correlated with biological
markers. First, numerous studies support the hypothesis that the
inﬂammatory response could have a strong inﬂuence on the outset
and development of schizophrenia and related disorders, and
numerous inﬂammatory markers have been linked with the cognitive
state of patients with these illnesses. Because cognitive deterioration
has a direct impact on overall functioning in schizophrenia, the
development of efﬁcient therapies over the last few years has focused
on locating immunomodulatory or anti-inﬂammatory drugs with
promising and hopeful results. However, there are still numerous
signiﬁcant aspects that need to be investigated further in future
studies, the most important of which include the following: (i) the
role of prolonged antipsychotic treatment in the inﬂammatoryresponse of patients with schizophrenia and their cognitive function;
(ii) the type and timing (with respect to disease stage) of the delivery
of anti-inﬂammatory or immunological therapies that are the most
suitable for producing short/long-term improvement in cognitive
responses; and (iii) whether dysregulation of the immune response is
a common characteristic of recently diagnosed patients or only of
particular pathological trajectories.
Second, the continued understanding of prolactin and its receptor
has greatly illuminated prolactin’s role in cognitive processes,
speciﬁcally in patients with schizophrenia and related disorders.
Recent studies have demonstrated prolactin’s importance both in the
transition to psychosis and in the prognosis and diagnosis of
schizophrenia independent of antipsychotic drug use, highlighting
the potential for it to become a schizophrenia-speciﬁc biomarker.
Despite the diversity of biomarkers associated with cognitive state
in schizophrenia, the current literature has gathered the greatest
amount of evidence for BDNF. Patients with schizophrenia demon-
strated lower concentrations of BDNF compared to healthy controls,
and a recent study correlates the levels of BDNF with improved
cognition in patients treated with cognitive rehabilitation
Taking into account the possible counterbalancing role of
neurotrophins, it is plausible both that early inﬂammation could
activate a response to increase the concentration of neurotrophic
factors and that this response could affect the response to treatment.
Therefore, it would be beneﬁcial to study the potential consequences
of the inﬂammatory state in the initial phases of psychosis and the
relevance of neurotrophic receptors in cognitive function and
treatment response. It is also necessary to understand the role played
by psychosocial stress as a trigger for these biological responses and
its detrimental consequences when, for example, stress is either
particularly acute or maintained for extended periods of time.
We thus expect considerable development in basic and clinical
research both on cognitive function and on potentially related
biomarkers, intended to transfer advances in neurosciences to the
ﬁeld of mental health, speciﬁcally the development of a greater
understanding of schizophrenia.Role of Funding Sources
The grants from the Instituto de Salud Carlos of FIS (PI 11/01958)
to R Penadés, FIS (PI14/00753) to C Garcia-Rizo. A González-Rodrí-
guez has received the First Juan José López-Ibor Foundation Grant for
young Researchers.Gisela Mezquida was supported by the Catalonian
Government (2014- SGR-1573 to the Research Unit of FIDMAG and
2014-SGR-441 to Barcelona Clinic Schizophrenia Unit) and the gran
FI-DGR-2013 Contract of the Agència de Gestió d’Ajuts Universitaris i
de Recerca (AGAUR) (2015 FI_B2 00100).Contributors
RP,CG, MB, AG-R, BC, GM and MB wrote the ﬁrst draft of the
manuscript and reviewed it.Conﬂict of Interest
R Penadés has received honoraria/travel suport from Otsuka-Lund-
beck. C Garcia Rizo has received honoraria/travel support from Janssen--
Cilag, Lundbeck and Ferrer. Alexandre González-Rodríguez has received
honoraria or paid for travels from Pﬁzer, Ferrer, Janssen-Cilag, and
Lundbeck-Otsuka.Acknowledgements
The authors thank the Barcelona Clinic Schizophrenia Unit
members for their assistance.
177R. Penadés et al. / Schizophrenia Research: Cognition 2 (2015) 172–178References
Amani, A., Alamolhodaei, S.H., Radmehr, F., 2012. The relationship between students’
cognitive abilities, mathematical performance and the level of testosterone,
thyroid-stimulating hormone, prolactin and thyroxine. JMCS 5 (1), 1–16.
Aston, J., Rechsteiner, E., Bull, N., Borgwardt, S., Gschwandtner, U., Riecher-Rössler, A.,
2010 Oct 1. Hyperprolactinaemia in early psychosis-not only due to antipsychotics.
Prog Neuropsychopharmacol Biol Psychiatry 34 (7), 1342–1344.
Atkinson, A.J., Colburn, W.A., DeGruttola, V.G., DeMets, D.L., Downing, G.J., Hoth, D.F., et
al., 2001. Biomarkers and surrogate endpoints: Preferred deﬁnitions and
conceptual framework. Clin. Pharmacol. Ther. 69 (3), 89–95.
Bekinschtein, P., Cammarota, M., Katche, C., Slipczuk, L., Rossato, J.I., Goldin, A.,
Izquierdo, I., Medina, J.H., 2008. BDNF is essential to promote persistence of long-
term memory storage. Proc. Natl. Acad. Sci. U. S. A. 105 (7), 2711–2716.
Benarroch, E.E., 2013. Microglia: Multiple roles in surveillance, circuit shaping, and
response to injury. Neurology 81 (12), 1079–1088.
Ben-Jonathan, N., LaPensee, C.R., LaPensee, E.W., 2008. What can we learn from rodents
about prolactin in humans? Endocr. Rev. 29 (1), 1–41.
Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B.,
2011. Autoimmune diseases and severe infections as risk factors for schizophrenia:
A 30-year population-based register study. Am. J. Psychiatry 168 (12), 1303–1310.
Bernichtein, S., Touraine, P., Gofﬁn, V., 2010. New concepts in prolactin biology.
J. Endocrinol. 206 (1), 1–11.
Bioque, M., García-Bueno, B., Macdowell, K.S., Meseguer, A., Saiz, P.A., Parellada, M.,
Gonzalez-Pinto, A., Rodriguez-Jimenez, R., Lobo, A., Leza, J.C., Bernardo, M., FLAMM-
PEPs study- Centro de Investigación Biomédica en Red de Salud Mental, 2013.
Peripheral endocannabinoid system dysregulation in ﬁrst-episode psychosis.
Neuropsychopharmacology 38 (13), 2568–2577.
Byerly, M., Suppes, T., Tran, Q.V., Baker, R.A., 2007. Clinical implications of
antipsychotic-induced hyperprolactinemia in patients with schizophrenia spec-
trum or bipolar spectrum disorders: Recent developments and current perspec-
tives. J. Clin. Psychopharmacol. 27 (6), 639–661.
Castanho, T.C., Moreira, P.S., Portugal-Nunes, C., Novais, A., Costa, P.S., Palha, J.A., Sousa,
N., Santos, N.C., 2010. The role of sex and sex-related hormones in cognition, mood
and well-being in older men and women. Biol. Psychol. 103C, 158–166.
Chana, G., Bousman, C.A., Money, T.T., Gibbons, A., Gillett, P., Dean, B., Everall, I.P., 2013.
Biomarker investigations related to pathophysiological pathways in schizophrenia
and psychosis. Front Cell Neurosci 26 (7), 95.
Correll, C.U., 2014. Mechanism of action of antipsychotic medications. J. Clin. Psychiatry
75 (4), 347–348.
Das, I., Khan, N.S., 1998. Increased arachidonic acid induced platelet chemilumines-
cence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglan-
dins Leukot. Essent. Fat. Acids 58 (3), 165–168.
Dickerson, F., Stallings, C., Origoni, A., Boronow, J., Yolken, R., 2007. C-reactive protein is
associated with the severity of cognitive impairment but not of psychiatric
symptoms in individuals with schizophrenia. Schizophr. Res. 93 (1), 261–265.
Drexhage, R.C., van der Heul-Nieuwenhuijsen, L., Padmos, R.C., van Beveren, N., Cohen,
D., Versnel, M.A., Nolen, W.A., Drexhage, H.A., 2010. Inﬂammatory gene expression
in monocytes of patients with schizophrenia: Overlap and difference with bipolar
disorder. A study in naturalistically treated patients. Int. J. Neuropsychopharmacol.
13 (10), 1369–1381.
Eggan, S.M., Hashimoto, T., Lewis, D.A., 2008. Reduced cortical cannabinoid 1 receptor
messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 65
(7), 772–784.
Farrar, D., Tuffnell, D., Neill, J., Scally, A.,Marshall, K., 2014. Assessment of cognitive function
across pregnancy using CANTAB: A longitudinal study. Brain Cogn. 84 (1), 76–84.
Fineberg, A.M., Ellman, L.M., 2013. Inﬂammatory cytokines and neurological and
neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 73 (10),
951–966.
Gama, C.S., Andreazza, A.C., Kunz, M., 2007. Serum levels of brain-derived neurotrophic
factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 420 (1),
45–48.
García-Bueno, B., Bioque,M.,Mac-Dowell, K.S., Barcones,M.F.,Martínez-Cengotitabengoa,M.,
Pina-Camacho, L., Rodríguez-Jiménez,R., Sáiz, P.A., Castro, C., Lafuente,A., Santabárbara, J.,
González-Pinto, A., Parellada, M., Rubio, G., García-Portilla, M.P., Micó, J.A., Bernardo, M.,
Leza, J.C., 2014a. Pro-/anti-inﬂammatory dysregulation in patients with ﬁrst episode
of psychosis: Toward an integrative inﬂammatory hypothesis of schizophrenia.
Schizophr. Bull. 40 (2), 376–387 PMID: 23486748.
García-Bueno, B., Bioque,M.,Mac-Dowell, K.S., Santabárbara, J.,Martínez-Cengotitabengoa,M.,
Moreno, C., Saiz, P.A., Berrocoso, E., Gassó, P., Barcones, M.F., González-Pinto, A., Parellada,
M., Bobes, J., Micó, J.A., Bernardo, M., Leza, J.C., 2014 Oct 31b. Pro-/Antiinﬂammatory
Dysregulation in Early Psychosis: Results from a 1-Year Follow-Up Study. Int.
J. Neuropsychopharmacol. 18 (2) PMID: 25577666.
Garcia-Rizo, C., Fernandez-Egea, E., Oliveira, C., Justicia, A., Parellada, E., Bernardo, M.,
Kirkpatrick, B., 2012 Jan. Prolactin concentrations in newly diagnosed, antipsy-
chotic-naïve patients with nonaffective psychosis. Schizophr Res. 134 (1), 16–19.
Gärtner, A., Polnau, D.G., Staiger, V., et al., 2006. Hippocampal long-term potentiation is
supported by presynaptic and postsynaptic tyrosine receptor kinase B-mediated
phospholipase Cgamma signaling. J. Neurosci. 26 (13), 3496–3504.
Giuffrida, A., Leweke, F.M., Gerth, C.W., Schreiber, D., Koethe, D., Faulhaber, J.,
Klosterkotter, J., Piomelli, D., 2004. Cerebrospinal anandamide levels are elevated
in acute schizophrenia and are inversely correlated with psychotic symptoms.
Neuropsychopharmacology 29 (11), 2108–2114.Grattan, D.R., 2002. Behavioural signiﬁcance of prolactin signalling in the central
nervous system during pregnancy and lactation. Reproduction 123 (4), 497–506.
Grattan, D.R., Kokay, I.C., 2008. Prolactin: A pleiotropic neuroendocrine hormone.
J. Neuroendocrinol. 20 (6), 752–763.
Green, M.F., Kern, R.S., Braff, D.L., Mintz, J., 2000. Neurocognitive deﬁcits and functional
outcome in schizophrenia: Are we measuring the “right stuff”? Schizophr. Bull. 26
(1), 119–136.
Green, M.J., Matheson, S.L., Shepherd, A., Weickert, C.S., Carr, V.J., 2011. Brain-derived
neurotrophic factor levels in schizophrenia: A systematic review with meta-
analysis. Mol. Psychiatry 16 (9), 960–972.
Grillo, R.W., Ottoni, G.L., Leke, R., Souza, D.O., Portela, L.V., Lara, D.R., 2007. Reduced
serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics.
J. Psychiatr. Res. 41 (1-2), 31–35.
Henry, J.F., Sherwin, B.B., 2011. Hormones and cognitive functioning during late
pregnancy and postpartum: A longitudinal study. Behav. Neurosci. 126 (1), 73–85.
Horseman, N.D., Gregerson, K.A., 2013. Prolactin actions. J. Mol. Endocrinol. 52 (1),
R95–R106.
Ichioka, S., Terao, T., Hoaki, N., Matsushita, T., Hoaki, T., 2012. Triiodothyronine may be
possibly associated with better cognitive function and less extrapyramidal
symptoms in chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry
39 (1), 170–174.
Ikeda, Y., Yahata, N., Ito, I., Nagano, M., Toyota, T., Yoshikawa, T., et al., 2008. Low serum
levels of brain-derived neurotrophic factor and epidermal growth factor in patients
with chronic schizophrenia. Schizophr. Res. 101 (1-3), 58–66.
Insel, T.R., 2010. Rethinking schizophrenia. Nature 468 (7321), 187–193.
Ishiguro, H., Horiuchi, Y., Ishikawa, M., Koga, M., Imai, K., Suzuki, Y., Morikawa, M.,
Inada, T., Watanabe, Y., Takahashi, M., Someya, T., Ujike, H., Iwata, N., Ozaki, N.,
Onaivi, E.S., Kunugi, H., Sasaki, T., Itokawa, M., Arai, M., Niizato, K., Iritani, S., Naka, I.,
Ohashi, J., Kakita, A., Takahashi, H., Nawa, H., Arinami, T., 2010. Brain cannabinoid
CB2 receptor in schizophrenia. Biol. Psychiatry 67 (10), 974–982.
Jaroenporn, S., Nagaoka, K., Kasahara, C., Ohta, R., Watanabe, G., Taya, K., 2007.
Physiological roles of prolactin in the adrenocortical response to acute restraint
stress. Endocr. J. 54 (5), 703–711.
Kaiya,H., Uematsu,M., Ofuji,M.,Nishida, A., Takeuchi,K., Nozaki,M., Idaka, E., 1989. Elevated
plasma prostaglandin E2 levels in schizophrenia. J. Neural Transm. 77 (1), 39–46.
Karege, F., Schwald,M., Cisse,M., 2002. Postnatal developmental proﬁle of brain-derived
neurotrophic factor in rat brain and platelets. Neurosci. Lett. 328 (3), 261–264.
Kirkpatrick, B., 2009. The concept of schizophrenia. Rev. Psiquiatr. Salud Ment. 2 (3),
105–107.
Kroken, R.A., Løberg, E.-M., Drønen, T., Gruner, R., Hugdahl, K., Kompus, K., Skrede, S.,
Johnsen, E., 2014. A critical review of pro-cognitive drug targets in psychosis:
Convergence on myelination and inﬂammation. Front. Psychiatry 4, 5–11.
Le, J.A., Wilson, H.M., Shehu, A., Devi, Y.S., Aguilar, T., Gibori, G., 2011. Prolactin
activation of the long form of its cognate receptor causes increased visceral fat and
obesity inmales as shown in transgenic mice expressing only this receptor subtype.
Horm. Metab. Res. 43 (13), 931–937.
Lee, B.J., Lee, S.J., Kim,M.K., Lee, J.G., Park, S.W., Kim,G.M., Kim,Y.H., 2013. Effect of aripiprazole
on cognitive function and hyperprolactinemia in patients with schizophrenia treated
with risperidone. Clin. Psychopharmacol. Neurosci. 11, 60–66.
Levkovitz, Y., Mendlovich, S., Riwkes, S., et al., 2010. A double-blind, randomized study
of minocycline for the treatment of negative and cognitive symptoms in early-
phase schizophrenia. J. Clin. Psychiatry 71 (2), 138–149.
Leweke, F.M., Giuffrida, A., Wurster, U., Emrich, H.M., Piomelli, D., 1999. Elevated
endogenous cannabinoids in schizophrenia. Neuroreport 10 (8), 1665–1669.
Maes, M., Bosmans, E., Calabrese, J., Smith, R., Meltzer, H.Y., 1995. Interleukin-2 and
interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood
stabilizers. J. Psychiatr. Res. 29 (2), 141–152.
Martinez-Gras, I., Perez-Nievas, B.G., Garcia-Bueno, B., Madrigal, J.L., Andres-Esteban, E.,
Rodriguez-Jimenez, R., Hoenicka, J., Palomo, T., Rubio, G., Leza, J.C., 2011. The anti-
inﬂammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are
decreased in schizophrenia. Schizophr. Res. 128 (1-3), 15–22.
McAfoose, J., Baune, B.T., 2009. Evidence for a cytokine model of cognitive function.
Neurosci. Biobehav. Rev. 33 (3), 355–366.
Metzger, W.J., Butler, J.E., Swanson, P., Reinders, E., Richardson, H.B., 1981. Ampliﬁca-
tion of the enzime-linked immunosorbent essay for measuringaliergen-speciﬁc lgE
and lgG antibody. Clin. Allergy 11 (6), 523–531.
Meyer, U., 2011. Anti-inﬂammatory signaling in schizophrenia. Brain Behav. Immun. 25
(8), 1507–1518.
Meyer, U., Schwarz, M.J., Muller, N., 2011. Inﬂammatory processes in schizophrenia: A
promising neuroimmunological target for the treatment of negative/cognitive
symptoms and beyond. Pharmacol. Ther. 132 (1), 96–110.
Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., 2011. Meta-analysis of
cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol.
Psychiatry 70 (7), 663–671.
Minichiello, L., Korte, M., Wolfer, D., et al., 1999. Essential role for TkB receptors in
hippocampus-mediated learning. Neuron 24, 401–414.
Montalvo, I., Gutierrez-Zotes, A., Creus, M., Monseny, R., Ortega, L., Franch, J., Lawrie, S.M.,
Reynolds, R.M., Vilella, E., Labad, J., 2014. Increased prolactin levels are associatedwith
impaired processing speed in subjects with early psychosis. PLoS One 9 (2), e89428.
Moore, L., Kyaw, M., Vercammen, A., Lenroot, R., Kulkarni, J., Curtis, J., O'Donnell, M.,
Carr, V.J., ShannonWeickert, C., Weickert, T.W., 2013. Serum testosterone levels are
related to cognitive function in men with schizophrenia. Psychoneuroendocrinol-
ogy 38 (9), 1717–1728.
178 R. Penadés et al. / Schizophrenia Research: Cognition 2 (2015) 172–178Morena, M., Campolongo, P., 2013. The endocannabinoid system: An emotional buffer
in the modulation of memory function. Neurobiol. Learn. Mem. 112, 30–43.
Muguruza, C., Lehtonen, M., Aaltonen, N., Morentin, B., Meana, J.J., Callado, L.F., 2013.
Quantiﬁcation of endocannabinoids in postmortem brain of schizophrenic subjects.
Schizophr. Res. 148 (1-3), 145–150.
Muller, N., Riedel, M., Scheppach, C., et al., 2002. Beneﬁcial antipsychotic effects of
celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am.
J. Psychiatry 159 (6), 1029–1034.
Muller, N., Riedel, M., Schwarz, M.J., et al., 2005. Clinical effects of COX-2 inhibitors on
cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 255 (2), 149–151.
Nakajo, Y., Miyamoto, S., Nakano, Y., Xue, J.H., Hori, T., Yanamoto, H., 2008. Genetic
increase in brain-derived neurotrophic factor levels enhances learning and
memory. Brain Res. 1241, 103–109.
Niitsu, T., Shirayama, Y., Matsuzawa, D., Hasegawa, T., Kanahara, N., Hashimoto, T., et al.,
2011. Associations of serum brain-derived neurotrophic factor with cognitive
impairments and negative symptoms in schizophrenia. Prog. Neuropsychophar-
macol. Biol. Psychiatry 35 (8), 1836–1840.
Nitta, M., Kishimoto, T., Muller, N., Weiser, M., Davidson, M., Kane, J.M., Correll, C.U., 2013.
Adjunctive use of nonsteroidal anti-inﬂammatory drugs for schizophrenia: A meta-
analytic investigation of randomized controlled trials. Schizophr. Bull. 39 (6), 1230–1241.
Oertel-Knöchel, V., Bittner, R.A., Knöchel, C., Prvulovic, D., Hampel, H., 2011. Discovery
and development of integrative biological markers for schizophrenia. Prog.
Neurobiol. 95 (4), 686–702.
Penadés, R., Catalán, R., López-Vílchez, I., Arias, B., González-Rodríguez, A., Galán, A.M.,
Gastó, C., 2013. Brain-derived neurotrophic factor as a potential biomarker of
cognitive recovery in schizophrenia. World J. Psychiatry 3 (4), 93–102.
Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E., 2008. Inﬂammatory
cytokine alterations in schizophrenia: A systematic quantitative review. Biol.
Psychiatry 63 (8), 801–808.
Reis, H.J., Nicolato, R., Barbosa, I.G., Teixeira do Prado, P.H., Romano-Silva, M.A., Teixeira,
A.L., 2008. Increased serum levels of brain-derived neurotrophic factor in chronic
institutionalized patients with schizophrenia. Neurosci. Lett. 439 (2), 157–159.
Ribeiro-Santos, R., Lucio Teixeira, A., Vinicius Salgado, J., 2014. Evidence for an immune role on
cognition in schizophrenia: A systematic review. Curr. Neuropharmacol. 12 (3), 273–280.
Roelfsema, F., Pijl, H., Keenan, D.M., Veldhuis, J.D., 2012. Prolactin secretion in healthy
adults is determined by gender, age and body mass index. PLoS One 7 (2), e31305.
Saetre, P., Emilsson, L., Axelsson, E., Kreuger, J., Lindholm, E., Jazin, E., 2007. Inﬂammation-
related genes up-regulated in schizophrenia brains. BMC Psychiatry 7, 46.
Schizophrenia Working Group of the Psychiatric Genomics, C, 2014. Biological insights
from 108 schizophrenia-associated genetic loci. Nature 511 (7510), 421–427.
Shi, J., Levinson, D.F., Duan, J., Sanders, A.R., Zheng, Y., Pe'er, I., Dudbridge, F., Holmans, P.A.,
Whittemore, A.S., Mowry, B.J., Olincy, A., Amin, F., Cloninger, C.R., Silverman, J.M.,
Buccola, N.G., Byerley, W.F., Black, D.W., Crowe, R.R., Oksenberg, J.R., Mirel, D.B.,
Kendler, K.S., Freedman, R., Gejman, P.V., 2009. Common variants on chromosome
6p22.1 are associated with schizophrenia. Nature 460 (7256), 753–757.
Sommer, I.E., van Westrhenen, R., Begemann, M.J., de Witte, L.D., Leucht, S., Kahn, R.S.,
2014. Efﬁcacy of anti-inﬂammatory agents to improve symptoms in patients with
schizophrenia: An update. Schizophr. Bull. 40 (1), 181–191.
Stefansson, H., Ophoff, R.A., Steinberg, S., Andreassen, O.A., Cichon, S., Rujescu, D.,
Werge, T., Pietilainen, O.P., Mors, O., Mortensen, P.B., Sigurdsson, E., Gustafsson, O.,
Nyegaard, M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist,
J., Paunio, T., Borglum, A.D., Hartmann, A., Fink-Jensen, A., Nordentoft, M.,
Hougaard, D., Norgaard-Pedersen, B., Bottcher, Y., Olesen, J., Breuer, R., Moller,
H.J., Giegling, I., Rasmussen, H.B., Timm, S., Mattheisen, M., Bitter, I., Rethelyi, J.M.,
Magnusdottir, B.B., Sigmundsson, T., Olason, P., Masson, G., Gulcher, J.R.,
Haraldsson, M., Fossdal, R., Thorgeirsson, T.E., Thorsteinsdottir, U., Ruggeri, M.,
Tosato, S., Franke, B., Strengman, E., Kiemeney, L.A., Melle, I., Djurovic, S., Abramova,
L., Kaleda, V., Sanjuan, J., de Frutos, R., Bramon, E., Vassos, E., Fraser, G., Ettinger, U.,
Picchioni, M., Walker, N., Toulopoulou, T., Need, A.C., Ge, D., Yoon, J.L., Shianna, K.V.,
Freimer, N.B., Cantor, R.M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango,C., Costas, J., Jonsson, E.G., Terenius, L., Agartz, I., Petursson, H., Nothen, M.M.,
Rietschel, M., Matthews, P.M., Muglia, P., Peltonen, L., St Clair, D., Goldstein, D.B.,
Stefansson, K., Collier, D.A., 2009. Common variants conferring risk of schizophre-
nia. Nature 460 (7256), 744–747.
Sugino, H., Futamura, T., Mitsumoto, Y., Maeda, K., Marunaka, Y., 2009. Atypical
antipsychotics suppress production of proinﬂammatory cytokines and up-regulate
interleukin-10 in lipopolysaccharide-treated mice. Prog. Neuropsychopharmacol.
Biol. Psychiatry 33 (2), 303–307.
Tan, Y.L., Zhou, D.F., Cao, L.Y., Zou, Y.Z., Zhang, X.Y., 2005. Decreased BDNF in serum of
patients with chronic schizophrenia on long-term treatment with antipsychotics.
Neurosci. Lett. 382 (1-2), 27–32.
Tandon, R., Nasrallah, H.A., Keshavan, M.S., 2010. Schizophrenia, “just the facts” 5. Treatment
and prevention. Past, present, and future. Schizophr. Res. 122 (1-3), 1–23.
Torner, L., Tinajero, E., Lajud, N., Quintanar-Stephano, A., Olvera-Cortes, E., 2013.
Hyperprolactinemia impairs object recognition without altering spatial learning in
male rats. Behav. Brain Res. 252, 32–39.
Torrey, E.F., Bartko, J.J., Yolken, R.H., 2012. Toxoplasma gondii and other risk factors for
schizophrenia: An update. Schizophr. Bull. 38 (3), 642–647.
Trajkovska, V., Marcussen, A.B., Vinberg, M., Hartvig, P., Aznar, S., Knudsen, G.M., 2007.
Measurements of brain-derived neurotrophic factor: Methodological aspects and
demographical data. Brain Res. Bull. 73 (1-3), 143–149.
Upthegrove, R., Manzanares-Teson, N., Barnes, N.M., 2014. Cytokine function in
medication-naive ﬁrst episode psychosis: A systematic review and meta-analysis.
Schizophr. Res. 155 (1-3), 101–108.
Van Berckel, B.N., Bossong, M.G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E.,
Luurtsema, G., Windhorst, A.D., Cahn, W., Lammertsma, A.A., Kahn, R.S., 2008.
Microglia activation in recent-onset schizophrenia: A quantitative (R)-
[11C]PK11195 positron emission tomography study. Biol. Psychiatry 64 (9),
820–822.
Vermeulen, A., Kaufman, J.M., Goemaere, S., van Pottelberg, I., 2002. Estradiol in elderly
men. Aging Male 5 (2), 98–102.
Vinogradov, S., Fisher, M., Holland, C., Shelly, W., Wolkowitz, O., Mellon, S.H., 2009. Is
serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in
schizophrenia? Biol. Psychiatry 66 (6), 549–553.
Walker, T.L., Vukovic, J., Koudijs, M.M., Blackmore, D.G., Mackay, E.W., Sykes, A.M.,
Overall, R.W., Hamlin, A.S., Bartlett, P.F., 2012. Prolactin stimulates precursor cells
in the adult mouse hippocampus. PLoS One 7 (9), e44371.
Wolf, S.A., Tauber, S., Ullrich, O., 2008. CNS immune surveillance and neuroin-
ﬂammation: Endocannabinoids keep control. Curr. Pharm. Des. 14 (23),
2266–2278.
Xiu, M.H., Hui, L., Dang, Y.F., Hou, T.D., Zhang, C.X., Zheng, Y.L., et al., 2009. Decreased
serum BDNF levels in chronic institutionalized schizophrenia on long-term
treatment with typical and atypical antipsychotics. Prog. Neuropsychopharmacol.
Biol. Psychiatry 33 (8), 1508–1512.
Yasui-Furukori, N., Furukori, H., Sugawara, N., Fujii, A., Kaneko, S., 2010. Dose-
dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia
induced by risperidone in female patients with schizophrenia. J. Clin. Psychophar-
macol. 30 (5), 596–599.
Yasui-Furukori, N., Kaneda, A., Sugawara, N., Tomita, T., Kaneko, S., 2011. Effect of
adjunctive treatment with aripiprazole to atypical antipsychotics on
cognitive function in schizophrenia patients. J. Psychopharmacol. 26 (6),
806–812.
Zamberletti, E., Rubino, T., Parolaro, D., 2012. The endocannabinoid system and
schizophrenia: Integration of evidence. Curr. Pharm. Des. 18 (32), 4980–4990.
Zhang, X.Y., Tan, Y.L., Zhou, D.F., Cao, L.Y., Wu, G.Y., Xu, Q., et al., 2007. Serum BDNF
levels and weight gain in schizophrenic patients on long-term treatment with
antipsychotics. J. Psychiatr. Res. 41 (12), 997–1004.
Zhang, X.Y., Liang, J., Chen, D.C., Xiu, M.H., De Yang, F., Kosten, T.A., et al., 2012. Low
BDNF is associated with cognitive impairment in chronic patients with schizo-
phrenia. Psychopharmacology (Berl) 222 (2), 277–284.
